48 / 52
Page 131
conferenceseries
.com
Volume 8, Issue 2 (Suppl)
Chem Sci J 2017
ISSN: 2150-3494 CSJ, an open access journal
Euro Chemistry 2017
May 11-13, 2017
May 11-13, 2017 Barcelona, Spain
4
th
European Chemistry Congress
Chem Sci J 2017, 8:2(Suppl)
http://dx.doi.org/10.4172/2150-3494-C1-009Catalysis by Copper Derivatives in Substitution and Addition Reactions
Irina P Beletskaya
Moscow State University, Russian Federation
In this presentation two types of processes will be considered.
1. Cross-coupling reactions of carbon-carbon and carbon-heteroatombond formation (including the reactions of C-H activation)
2. The addition of S-H, Se-H, P-H, H-H bonds to alkynes, alkenes and imines (including asymmetric Friedel-Crafts/Michael
addition reactions).
beletska@org.chem.msu.ruSurface Derivatization of Zirconium Phosphate Nanoplatelets: Potential Nanocarrier of Doxorubicin
Anticancer Drug
Julissa Gonzalez Villegas
University of Puerto, United States
S
urface modification of doxorubicin anticancer drug (DOX) intercalated zirconium phosphate (ZrP) nanoparticles (DOX@ZrP)
is proposed to improve the potential of this drug delivery system for cancer therapy. The surface of DOX@ZrP nanoparticles
was modified with an amorphous layer of Zr(IV) followed by modification with monomethyl-polyethylene glycol-monophosphate
(m-PEG-PO3) to increase the DOX@ZrP biocompatibility.
31
P{
1
H}MAS NMR data shows a new peak at -26 ppm corresponding to
the PO
4
3-
groups coordinated with Zr(IV) on the surface. m-PEG-PO
3
/Zr(IV)/DOX@ZrP spectra shows no additional resonance
centered at δ of -22.6 ppm generated by proton-phosphorous cross polarization indicating no partial PEG intercalation in the
interlaminar space. Simulated body fluid (SBF) was used to determine the
in vitro
release of DOX from DOX@ZrP, Zr(IV)/DOX@
ZrP, and m-PEG-PO
3
/ Zr(IV)/DOX@ZrP. MTS cell viability assay reveal that m-PEG-PO
3
/ Zr(IV)/DOX@ZrP exhibited a 20%
increase in the toxicity comparing with free DOX when PC3 cells are exposed for 48 h. m-PEG-PO3 polymer coating of DOX@ZrP
nanoparticles promise to have a strong impact on the targeting, distribution and degradation of the nanoparticles under physiological
environment that should result in a more efficient chemotherapy agent than free doxorubicin.
jgonvi1888@gmail.com